Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(acetylamino)-5-amino-3-hydroxybenzoic acid
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
4-(acetylamino)-5-amino-3-hydroxybenzoic acid is a synthetic small molecule belonging to the class of acylaminobenzoic acids and derivatives. It is characterized by an acetylamino group at position 4, an amino group at position 5, and a hydroxy group at position 3 on the benzoic acid core. The compound has not been approved for any therapeutic use and is classified as experimental. There are no known clinical trials or approved indications for this molecule, and its mechanism of action, pharmacological activity, or potential therapeutic applications have not been established in the literature[1].
- Other names
- 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID
Beyond the preview
Go deeper on 4-(acetylamino)-5-amino-3-hydroxybenzoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-(acetylamino)-5-amino-3-hydroxybenzoic acid.